Comparative analysis of age-related degeneration risk factors among young people from northern and southern regions

Purpose. To analyse and compare the main risk factors for macular degeneration among young people from northern and southern regions. Material and methods. The survey involved 120 students from North - West State Medical University I.I. Mechnikov and 132 from Astana Medical University, divided into 3 groups aged 17 to 25 years. For analysis, we used the «Screening Questionnaire for Determining the Risk of Age-related Macular Degeneration». Results and discussions. The study revealed the most common risk factors among young people, such as smoking, in particular, among people with hereditary predisposition and with a light color of the iris. Also, the study compares the prevalence of risk factors in northern and southern regions. Conclusions. Based on the results of the study, we should pay attention to the prevention of smoking among young people, to reduce the time spent on the computer, to inform about the need to use polarizing glasses. Key words: age-related macular degeneration, risk factors, young age, heredity, smoking, iris colour.

Download Full-text

Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration

Scientific Reports ◽

10.1038/s41598-021-91832-w ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Maiko Maruyama-Inoue ◽

Tatsuya Inoue ◽

Shaheeda Mohamed ◽

Yoko Kitajima ◽

Shoko Ikeda ◽

...

Keyword(s):

Risk Factors ◽

Intraocular Pressure ◽

Macular Degeneration ◽

Intravitreal Injection ◽

Odds Ratio ◽

Japanese Patients ◽

Age Related Macular Degeneration ◽

Age Related ◽

Elevated Intraocular Pressure ◽

History Of

AbstractThe purpose of this study was to report the incidence of elevated intraocular pressure (IOP) after intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) in Japanese patients with age-related macular degeneration (AMD). A retrospective study of chart review of patients who underwent ≥ 10 intravitreal anti-VEGF injections between April 2009 and December 2019 was conducted. Elevated IOP was defined as IOP ≥ 25 mmHg at one visit. Cases with elevated IOP resulting from IVI were identified. Furthermore, the association between elevated IOP and some parameters, as the risk factors that influence elevated IOP, was investigated. A total of 402 eyes of 370 patients were included in this study. Twenty-eight eyes of 26 patients (7.0%) were identified as cases with elevated IOP after IVI. The mean time of elevation after baseline was 50.6 ± 26.5 months. History of glaucoma (p = 0.021; odds ratio, 5.85), treatment modality (p = 0.019; odds ratio, 6.32), and total number of injections (p = 0.003; odds ratio, 1.03) were significantly associated with elevated IOP. A late complication of elevated IOP is associated with IVI in patients with AMD. Particularly, history of glaucoma and treat and extend regimen with frequent injections were found to be risk factors of elevated IOP.

Download Full-text

Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy

International Journal of Molecular Sciences ◽

10.3390/ijms22031170 ◽

2021 ◽

Vol 22 (3) ◽

pp. 1170

Author(s):

Arunbalaji Pugazhendhi ◽

Margaret Hubbell ◽

Pooja Jairam ◽

Balamurali Ambati

Keyword(s):

Risk Factors ◽

Macular Degeneration ◽

Kinase Inhibitors ◽

Rho Kinase ◽

The Elderly ◽

Age Related Macular Degeneration ◽

Gene Therapies ◽

Rho Kinase Inhibitors ◽

Age Related ◽

Endothelial Growth Factor

Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD’s progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.

Download Full-text